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Abstract
Since almost 70% of the U.S. population over 20 years old is overweight and
30% is obese, with much of the western world following suit, many patients that will
potentially be administered circulating nanoparticles designed to localize to tumors and
avoid non-target areas will have significant amounts of white adipose tissue (WAT),
enlarged livers, and additional metabolic complications such as type 2 diabetes.
However, studies on nanoparticle biodistribution and efficacy take place almost without
exception in lean rodents with healthy metabolic states. In this work, I determined the
biodistribution of model nanoparticles – neutral filomicelles and polystyrene spheres
both carrying near infrared (NIR) dye - as a function of mouse diet, weight, and
metabolic condition. The livers of diet-induced obese mice show increased uptake of
nanoparticles, while mice with non-alcoholic fatty liver disease (NAFLD) do not see
increased uptake despite livers that are four fold as massive. Macrophages and
hepatocytes had increased particle internalization in vitro in media with increasing
amounts of fatty acids. From these observations, I postulate that the metabolic condition
of the patient will change the efficacy of current nanoparticle technologies.
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Chapter 1: Introduction

1-1 Nanoparticle Distribution and Metabolic State of the Patient
Obesity both increases the risk for certain cancers and worsens the chances of
survival, while physical activity during treatment improves patient outcomes [1].
Overweight and obese women diagnosed with breast cancer saw decreased rates of
survival; additionally, weight gain post-diagnosis has been shown to reduce survival
rates along with adverse body composition changes including an increase in fat mass,
while reductions in weight improved survivability [1]. Obesity not only effects the
treatment of diseases but also increases the risk of developing cancers. Obesity is the
second highest cause of cancer after tobacco [2]. Post-menopausal women with obesity
see elevated levels of the hormone estradiol, which has been linked to breast cancer
[3].
With over two thirds of Americans either overweight or obese, it is important to
consider the metabolic state of the typical patient receiving drug delivery treatments in
the form of nanoparticles [4]. Most studies of nanoparticle efficacy are carried out in
mice with ideal metabolic states that do not represent realistic clinical scenarios. Many
patients in the clinic with conditions that may require nanotechnology will be overweight
and obese. Those receiving treatment will typically have high levels of white adipose
tissue (WAT), may also suffer from other related conditions such as arteriolosclerosis,
fatty liver, and diabetes. In this work, I explored a subset of specific factors that may
affect the efficacy of nanoparticles. The goal of this work was to take an in-depth look at
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nanoparticle patient interactions based on metabolic state to further the advancement of
drug delivery vehicles in the treatment of cancer.
The elevated amount of WAT poses concerns that may impact nanoparticle
biodistribution and thus efficacy. Triacylglycerol, the main component of WAT is
hydrophobic as are many dyes and drugs carried by nanoparticles to identify and treat
tumors. These hydrophobic drugs may localize to these fat deposits and diminish the
impact on desired targets. Additionally, the number of macrophages increased from
10% of all cells in WAT of lean animals to more than 50% in cases of advanced obesity
[5]. Though often poorly vascularized, nanoparticles circulating through WAT could be
engulfed by the elevated level of macrophages and the T-cells that they regulate
preventing particles from reaching targets [6]. My in vitro work using murine
macrophages in conditions designed to induce the formation of lipid droplets further
showed potential for a reduction in nanoparticle efficacy due to elevated fat levels.
Macrophages with higher amounts of fat showed an increase in nanoparticle uptake.
One of the most challenging aspects of treating cancer in obese patients is the
difficulty in determining the correct dose to administer for effective treatment. These
considerations go far beyond the body mass index (BMI) and simple measures of body
fat of patients [7]. These dosing considerations are often inconsistent between different
types of cancers, or the appropriate measure, such as body surface area, may be
difficult to collect accurately [7-8]. Circulating plasma proteins, such as those related to
cholesterol and levels of inflammation both impact health, drug delivery and cancer
treatment. From development of atherosclerosis, to interactions with injected drugs,
understanding these proteins is an active health interest.

3
1-2 Current Cancer Treatment with Nanoparticles
The size, shape, charge, and surface chemistry all determine the fate and
distribution of nanoparticles [9-11]. Most cancer drugs are designed to take advantage
of the enhanced permeability and retention (EPR) effect where particles of diameters
between 10 and 200 nm are able to utilize the leaky vasculature surrounding solid
tumors and passively accumulate in the tissue surrounding the tumor. There are a
number of currently approved drugs that are designed with advantages over free drug
such as increased circulation, reduced negative side effects and improved efficacy.
These drugs include protein drug complexes and a variety of liposomes. Nanoparticles
that are currently available in the United States, Europe, or Asia for cancer treatment
are listed in Table 1-1. While these drugs are a hopeful advancement in treatment, they
are still subject to drawbacks that prevent widespread success [12].
Many polymer based nano carriers undergo accelerated blood clearance upon
repeated injections, which can cause difficulties with extended treatment, drug resistant
tumors, and recurring cancer [13-14]. Drugs in the typical size range for the EPR
effect—10 to 200 nm—are able to accumulate in the interstitial space of the tumor
vasculature but they often have trouble delivering drug homogeneously in the tumor
tissue or are unable to effectively transport drug past the tumor cell surface [12].
Polyethylene glycol, (PEG), is often used to modify the surface of particles to minimize
the immune response [9, 15]. Particles with a near neutral zeta potential typically see
the longest circulation times and have increased delivery efficiency compared to
negative and positively charged counterparts, which is related to both protein adsorption
and detection by the immune system [16]. The binding of serum proteins to
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Table 1-1. Nanoparticle Formulations Currently Approved for Cancer Treatment
Drug Name

Description

Abraxane

10 nm Albumin bound paclitaxel.

DaunoXome

50 nm Liposomal daunorubicin

Genexol-PM

20-50 nm Cremophor-free polymeric
micelle paclitaxel

Lipusu

Liposomal paclitaxel.

MM-398

100 nm Liposomal irinotecan.

Myocet

150-180 nm non-PEGylated liposomal
doxorubicin

PICN

100-110 nm Paclitaxel stabilized by
polymer and lipids
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nanoparticles in the blood does not necessarily correlate to reduced circulation time, as
nonspecific binding of proteins such as albumin has been shown to prolong particle
circulation times [12, 17]. Pre-incubation of particles with albumin has been shown to
decrease binding of specific whole plasma proteins and reduce clearance by
macrophages. These results on protein absorption and immune clearance show that not
only is the protein corona crucial in determining nanoparticle fate, but also required for
prolonged circulation.
Tumor Transport Properties
The tumor microenvironment presents challenges to drug transport and efficacy.
Drug carriers must traverse a series of stages to deliver drug to the tumor cells: blood
circulation, tumor vasculature, interstitial space, the tumor cell interior. Transvascular
transport is controlled through the pressure difference between the tumor vasculature
and the cells’ interstitial fluid as well as interactions between the particle and the surface
of the vessel walls. This pressure is determined by the permeability of the vessel walls,
which is highly variable between different cancer morphologies, and a dysfunctional
lymphatic system characterized by poor drainage and increased fluid flow to the
vasculature. High interstitial pressure often limits transport to diffusion, which is more
challenging for larger particles. Hindrance to transport can be size, charge, and
hydrodynamic effects as the particle diameter approaches the size of the pore opening.
While negatively charged and neutral particles often have increased circulation times,
positively charged particles often see greater transvascular transport due to affinity
towards the negatively charged vessel walls according to mathematical models [18-19].
Many nanocarriers are designed not to cross this barrier but rather to localize then
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release drug to diffuse into the tumor. Elongated particles of an aspect ratio greater than
four with the same hydrodynamic diameter of spherical particles experience greater flux
into tumor tissue possibly due to increased interactions with vascular walls when
tumbling and rolling.
Effective distribution in the tumor tissue is directly linked to improved patient
outcomes. Once inside the interstitial tumor tissue, transport remains limited by
diffusion. Due to the high interstitial pressure of a tumor, the drop to normal pressure at
the periphery of tumor can cause flux away from the target cells. Excessive extracellular
fibers may also hinder the distribution of particles with a diameter larger than 50 nm in
contrast to particles 5-50 nm, which generally diffuse homogenously in the tissue.
Positively and negatively charged particles both see decreased diffusivity due to
charged interactions with negatively charged hyaluronic acid, of the intracellular matrix
and positively charged collagen fibers. Flexible nanorods exhibit faster and more
uniform distribution compared to comparable spheres and ridged elongated particles.
While small particles diffuse rapidly, they are also cleared from the tumor tissue due to
poor retention compared to larger particles.
Similar to tumor angiogenesis, accumulation of white adipose tissue (WAT)
causes the growth of additional blood vessels. It is possible that some drug carriers
designed to utilize the EPR effect may see reduced efficacy due to the added blood
vessels in WAT. Some passive targeting of adipose vasculature has been seen in mice
of the diet induced obesity model; while targeting adipose tissue via the growth in
vascular architecture may be desirable in some applications, this may cause adverse
effects during cancer treatment [20-21].

7
Transport to the cell surface, internalization, and intracellular transport is likewise
a function of size, shape, charge and chemistry. Gold and silver nanoparticles undergo
receptor-mediated endocytosis most readily in the range 40-50 nm while larger particles
were unable to reach drug targets within the cell. Negatively charged particles, for
example carboxylated spheres, have in some systems shown increased cellular uptake
in vitro [18]. For particles under 100 nm in diameter, spherical particles are endocytosed
more readily than rod shaped particles however high aspect ratio particles larger than
100 nm diameter see more efficient uptake compared to spheres. Cellular uptake of
nanoparticles is less relevant in cases where drug delivery vehicles are designed to
release in the tumor microenvironment, for example by hydrolysis [22]. Tumor
penetrating peptides have been used successfully alongside Doxil, Abraxane, micelles,
iron oxide particles, quantum dots and hydrogels [12, 23].
Challenges in Drug Delivery of Nanoparticles
Size, shape, charge, and surface chemistry all determine the fate and distribution
of nanoparticles. Nanoparticles for drug delivery are typically limited to diameters from
10-200 nm. To take advantage of the larger, leaky vasculature of tumors, which causes
increased solid tumor drug localization (i.e. EPR), particles should be larger than the
healthy tissue pore dimeters of 6-12 nm [24-25]. Blood circulation clearance from
organs also limits particle size on the upper and lower ranges. Some drug targeting
strategies utilize multi-stage drug carriers to combine the circulation properties of
particles greater than 10 nm while releasing cargo capable of penetrating tumor tissue
and reaching drug targets within cells. Strategies include external thermal ablation and
reaction to the tumor microenvironment such as hydrolysis in lower pH environments
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[22, 26]. The altered condition of patients with non-ideal metabolic states may affect
how these particles react to the tumor environment with additional fatty acid present.
After intravenous injection, drug carriers experience a number of unique
constraints from interactions with organs, blood, and the mononuclear phagocyte
system. The size of blood vessels places an upper bound on particle size, which the
capillaries in the lungs are among the smallest, between 2 and 13 μm, as they are
meant to preferentially transport soft, deformable red blood cells over rigid white blood
cells [11]. Nanoparticles approaching this range can become sequestered in the lungs
where flexible particles or those of 3 to 6 μm are confined in the lungs temporarily, while
rigid particles may be unable to re-enter circulation [27]. This can also be a problem with
particle-particle interactions where smaller diameter carriers can aggregate and be
captured in the lung vasculature. Particles with a hydrodynamic diameter less than 5-6
nm are cleared by the kidneys, which for proteins is typically a molecular weight less
than 60 kDa [28]. Of the larger particles that are retained passing through the kidneys,
those larger than 200 nm are removed by the mononuclear phagocyte system, the liver
and the spleen [19]. For non-biodegradable carriers larger than 6 nm, the only excretion
pathway is through bile [11]. The ease of phagocytosis is mediated but the size, shape,
curvature and orientation of the particles; for non-spherical particles the angle of attack
in an important factor, where the contact with the larger dimension first slows uptake
[29-30]. The size limit for phagocytosis, determined in vitro, is 20 μm, which is larger
than a particle that could circulate freely in the vasculature [31]. Positively charged
particles are also cleared rapidly by the mononuclear phagocyte system. Proteins in the
blood plasma that influence the signaling and subsequent clearance by the immune
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system bind these positively charged nanoparticles [32]. Neutral charged particles, such
as polystyrene spheres, typically show longer circulation times when compared to their
charged analogous counterparts [32-33].
Macrophages make up a significant fraction of the immune response and were a
focus of in vitro investigation. The liver and spleen are the primary targets of
nanoparticle localization with macrophages contributing to particle capture in the liver.
Kupffer Cells, the macrophages localized to the liver, comprise 80-90% of tissueassociated macrophages [34-35]. Kupffer cells are involved in the liver’s response to
infection, toxins, injury repair, and inflammation [36]. The spleen is comprised of distinct
parts of red pulp containing macrophages and white pulp responsible for lymphocyte
proliferation, of both B and T cells. The spleen’s architecture is not consistent between
species, leading to different areas contributing to particle retention in mice versus
humans [11]. Nanoparticle localization to the spleen leads to increased nanoparticle
clearance on repeated injections, known as accelerated blood clearance [37].
Interactions of drug carriers with B-cells in the spleen induce the production of
circulating specific antibodies, which reduce the circulation times of PEG functionalized
nanoparticles [38-39]. Drug carriers conjugated to PEG that see decreased liver uptake
are retained by the spleen in greater quantities relative to non-PEG drug particles [4041]. Non-PEGylated particles are not significantly affected by accelerated blood
clearance on repeated injections mostly due to clearance by the liver before circulating
antibodies affect their fate [11].
Macrophages can be polarized into different activation states involving particle
uptake, inflammation, and debris clearance. Classically, macrophages are divided into
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three groups: inactive M0 macrophages, classically activated M1 macrophages, and
alternatively activated M2 macrophages. However it has been shown that these
activations states are not a simple polarization; some macrophages show mixed M1/M2
activation markers and various levels of pro or anti-inflammatory behavior [42]. WAT
macrophages show M2-like behavior as determined by metabolic activation rather than
classical pathways [43]. It is possible the metabolic activation of macrophages could
contribute to difficulties in treating diseases in patients with obesity. M2 macrophage
polarization is associated with increased particle uptake in WAT [44]. The inflammation
associated with this macrophage polarization is also associated with cancer
development [45-46].
Cells that are in high fat environments such as WAT store free fatty acids in
organelles called lipid droplets. Formation of lipid droplets in macrophages has been
simulated in vitro with the addition of both arachidonic acid and oleic acid, with
arachidonic acid showing increased droplet numbers and sizes [47]. Lipid droplets are
present in all cell types in the body and are involved in the management of excess fatty
acid that is typical of non-ideal metabolic states. The role of lipid content on the
internalization of particles was a focus of this research.
Modeling Obesity in Mice
Mouse models for obesity include diet-induced obesity and genetic modifications.
Mouse models can be used that not only alter metabolic state but also alter the levels of
circulating plasma proteins, cause accelerated atherosclerosis, and model relevant
diseases such as type 2 diabetes. The primary obesity model used in my experiments is
ob/ob mice that lack leptin, which regulates satiety leading to increased food
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consumption by the mice. A less severe obesity model, Ay/J, visibly characterized by
yellow fur, has increased fat mass compared to control mice. Mice with a knockout of
the LDLR liver receptor, have a reduced ability to remove low-density lipoproteins
(LDLs) from the blood resulting in two- to four-fold more total cholesterol due to higher
circulating LDL levels. High-density lipoprotein (HDL) levels remain relatively constant in
these mice [48]. High levels of LDL cholesterol relative to HDL cholesterol is a risk
factor for atherosclerosis and cardiovascular disease which is a leading cause of death
in the United States [49]. LDLR mice develop arterial lesions and eventually
atherosclerosis on a western diet, typically consisting of 17% kcal from fat. Alternatively,
a knockout of the SCARB1 receptor in the liver can increase circulating HDL levels.
Conversely, knockouts of required protein components of HDL, ApoA I and ApoA II, or
ApoB-100 for LDL can be used to reduce these cholesterol levels.
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Chapter 2: Investigating Filomicelles for Drug Delivery
Applications

2-1 Filomicelle Stability
Circulation times of days or weeks rather than hours are desirable for a variety of
drug delivery applications for the goal of lowering doses and longer periods of
bioavailability [50]. Filomicelles have diameters of ~50 nm and lengths up to 10 microns
having the shapes of filoviruses and have circulation times in mice of at least two days
[51-53].
Through various experiments we found the polybutadiene-polyethylene-glycol
(PBD-PEG) filomicelles to be stable at physiological conditions (Figure 2-1). However,
either the stability of various dyes or the ability of the micelles to hold cargo was
compromised by some separation techniques relative to the cargo retention in vivo and
in storage over two years at 4oC. The PBD-PEG filomicelles are stable in both length
and cargo retention at times longer than the two day length of our in vivo experiments.
Filomicelles after two weeks in physiological conditions - 37oC in phosphate buffered
saline (PBS) at pH 7.4 – are shown in Figure 2-2. The filomicelles and dye were stable
and visible through fluorescent microscopy up to 70 oC. While using hydrophobic PKH26
dye either through spectroscopy or fluorescent microscopy I found it became necessary
to add additional dye due to either a breakdown or loss of dye carried by the vehicles
after ultracentrifugation. Although the loss of dye would be useful in determining the
loading and delivery of drug, using only an initial addition of dye to the micelles proved
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A

HO-[CH2-CH2-O]m-b-[CO-[CH2]5=O]n-H

B
HO-[CH2-CH2-O]m-b-[CH2CH=CH-CH2]n-H

Figure 2-1. Filomicelle structure.
Polyethylene glycol (cyan) comprises the hydrophilic block of the copolymer whereas
either polybutadiene or polycaprolactone (red) comprise the hydrophobic block of the
copolymer. Hydrophobic dye molecules are represented by yellow spheres. The
chemistries of the two copolymers are shown: PEG-PBD (A) and PEG-PCL (B).
(Filomicelle cross-section structure by P. Dalhaimer.)
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Figure 2-2 Filomicelle with PKH26 dye after two weeks at 37oC
Filomicelles loaded with PKH26 dye (yellow spheres in Figure 2-1) were incubated in
PBS for two weeks at physiological temperature and pH retained dye and micelle
length. Scale bar is 10 μm.
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to only measure the stability of the dye, which was not as robust as the filomicelles
during ultracentrifugation.
In my experiments, I investigated the stability of the filomicelles and the leakage
of dye using the fluorescence of the loaded dye as a marker. Methods used to remove
excess

dye

or

isolate

nanoparticles

included

dialysis,

chromatography,

ultracentrifugation of the nanoparticles, and the addition of 3 μm polystyrene spheres,
which could be removed by centrifugation. Removing excess dye through dialysis is
possible due to the favorable partitioning of the dye inside the filomicelles. The
advantage of removal by 3 μm polystyrene beads is the use of a benchtop centrifuge at
17,000xg rather than an ultracentrifuge.
Ultracentrifugation is often used to separate nanoparticles of various sizes,
densities, and shapes and is used in binding affinity studies and in the characterization
of the proteins bound to the surfaces of nanoparticles either in the protein corona, or in
purification. Separating the filomicelles through centrifugation is desirable to measure
protein or potentially separate the longer particles. Ultracentrifugation of the filomicelles
proved difficult due to inconsistencies in the amount of particles left in the supernatant.
The fraction of nanoparticles removed from solution was to be measured by a reduction
in fluorescent PKH26 dye, via UV-vis. At speeds higher than 100,000xg, the micelles
began to lose the initially loaded dye while only a small fraction of nanoparticles were in
the pellet. While fluorescence in the solution diminished, the amount of filomicelles in
the pellet was negligible. This was determined by supplementing additional PKH26 dye
via fluorescent microscopy. Interestingly the fraction of filomicelles in the pellet does not
seem dependent on length. The cylindrical micelles are subject to tangling and
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clumping, especially in resuspended pelleted samples; however, many aggregated
filomicelles remained in the supernatant.
2-2 Separation of Filomicelles by Length
As with most if not all self-assembling systems, the lengths of filomicelles vary.
Longer filomicelles have been shown to be more effective in circulation and in targeting
solid mass tumors than shorter filomicelles [52]. Thus, I wished to separate the
filomicelles by length with the goal of keeping the longer filomicelles for in vivo
experiments and discarding the shorter filomicelles. Filomicelles were conjugated to
peptides to bind to various columns so they could be eluted by length. The idea was to
chemically cleave off the peptide after separation by length. SourceS and SourceQ
resins were used in combination with appropriate buffer, such as sodium phosphate,
sodium citrate, or Tris-HCl, based on the isoelectric point of the peptide. The filomicelles
showed weak column affinity.
Filomicelles have lengths ranging from 50 nm to ~10 microns. Given the wide
distribution of sizes, I attempted to separate the filomicelles through centrifugation due
to the differences in sedimentation rates. Despite large aggregates and other
complexes present, there presented no clear difference in the nanoparticles between
the pellet and supernatant even at speeds over 100,000xg.
2-3 Filomicelle surface modification
Many advances in nanoparticles as drug delivery vehicles require modification of
the surface with various functional groups: peptides and proteins. Targeted surface
moieties can increase localization, cell uptake, and circulation times. Peptides have
been used to avoid detection of the immune system and to target cancer cell surface
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markers which may be overexpressed [50]. To this end, I intended to use linker
chemistry, with Sulfo-NHS and EDC, to bind the N-terminus of peptides to a carboxylic
acid functionalized polymer. Commercially available COOH-PEG-PBD polymers were
significantly shorter than the polymer used to form filomicelles. Attempts to conjugate
peptides to filomicelle complexes with 0.1 wt% of COOH bound polymer were
unsuccessful. This is possibly due to the incompatible length or poor incorporation of
the COOH functionalized polymer into the micelles. Higher weight percentages of
COOH-PEG-PBD led to shorter, lower concentration filomicelles.
To produce polymer of the same length as those used in filomicelle preparation, I
used potassium permanganate to oxidize the hydroxy terminated PEG-PBD polymer to
produce a carboxylic acid. The reaction required dissolving the polymer in pyridine and
extraction with diethyl ether. In the future, this process could be avoided by
collaboration with the polymer synthesis process as the anionic polymerization can
easily substitute the reagent used to terminate the polymerization to produce COOHPEG-PBD. Producing functionalized polymer in the same batch as the base polymer will
remove variability in the use of differing polymer lengths or complex chemistries.
2-4 Materials and Methods
Filomicelle Preparation
Filomicelles were prepared with block copolymers through self-assembly using
two methods utilizing the evaporation of chloroform. For micelles based on PEG
(Polyethylene glycol) - PCL (Polycaprolactone) (Polymer Source Inc.), 50 mg of solid
copolymer was dissolved in 5 mL of chloroform (Fisher Scientific). 30 mL of PBS was
added to the chloroform solution and mixed on a stir plate at room temperature until the
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chloroform evaporated and the solution became opaque, which took approximately two
hours. All of the following steps were done at 4oC to reduce polymer degradation. The
polymer solution was centrifuged twice for five minutes at 17,000xg with the pellet
discarded each time [52].
PEG-PBD based filomicelles were produced through film evaporation. 100 mg of
PEG-PBD was dissolved in 10 mL of chloroform in a glass vial. Chloroform was
evaporated under flow of nitrogen while the vial was rotated to ensure even distribution
of polymer film. Once all visible chloroform was evaporated, the vial was placed under
flow of nitrogen for an additional 15 min. To promote self-assembly of micelles, 10 mL of
PBS was added to the dried film and placed in an oven at 60oC overnight.
Dye was loaded into the filomicelles after formations of the micelles by
hydrophobic association. Hydrophobic PKH26 dye (Sigma) was added at a ratio of 1 μL
dye for 1 mL of filomicelle solution and distributed into the filomicelles via pipette mixing.
Excess dye can be removed through dialysis, however very little excess dye is present
at this concentration.
Affinity Chromatography
Separation of filomicelles was done in a manually controlled flow column and an
FPLC. The advantage of the FPLC is the ability to use a controlled flow, up to 0.5
mL/min, and use a gradient of elution buffer. For the peptide A20.1, with an isoelectric
point less than 7, SourceQ beads were used with Sodium phosphate buffer at pH 7.4.
An elution buffer of sodium chloride was used as a gradient up to 1M and manually
added as 1M. For the peptide A20.36, with an isoelectric point above 7, SourceS beads
were used with Tris-HCl buffer pH 7.
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2-5 Results and Discussion
The filomicelles proved to be robust in high sheer, high temperature, and in the
presence of plasma proteins. Difficulty purifying and separating exact amounts of
filomicelles could prove challenging when these techniques are vital to their use as a
drug delivery vehicle in a clinical setting. Theoretically long cylindrical particles should
be able to cross through filtration membranes as long flexible polymers of similar
dimensions are able to pass while stiff polymers do not [54]. However, the filomicelles
do not pass through a 100KDa MW centrifugal filter. While this filter retention can be
advantageous for the isolation and characterization of the filomicelles for examining
protein-filomicelle affinity or quantifying the amount of filomicelles present in a blood
sample, ability to filter sterilize is important in the use as a clinical drug carrier.
The idea of binding filomicelles to an affinity column through the attachment of
peptides should be explored further. Adding a defined range of micelle lengths rather
than the range of 40 nm spheres to cylinders tens of microns long, would allow for more
control on particle circulation time and fate. These experiments were incomplete without
the adequate polymer chemistry and remain useful beyond separation by size.
Purification by affinity column ensures micelles that were not functionalized with
targeting peptide are removed from the same.
It remains unclear why the PBD-PEG filomicelles are unable to be separated via
ultracentrifugation while the PKH26 dye comes out of solution. Attempts to pellet the
filomicelles at speeds greater than 100,000xg for one hour were unsuccessful. This is
surprising as other micelles, including cylindrical micelles, have been pelleted via
ultracentrifugation at lower speeds [55]. It is possible that these PBD-PEG filomicelles
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are too similar or lower in density compared to water to see significant sedimentation. In
further experiments investigating blood plasma protein filomicelle binding using
ultracentrifugation, an increasing amount of protein is pelleted without any interactions
with nanoparticles as higher centrifuge speeds were attempted. Control centrifugations
with blood plasma alone showed no difference between samples with and without
nanoparticles. As particle-protein interactions have become my primary use of
ultracentrifugation, I have avoided using solvents other than water that may affect the
particle-protein equilibrium. Using separation methods such as a sucrose gradient may
be necessary in the future to isolate filomicelles via ultracentrifugation.

22

Chapter 3: Nanoparticle Studies in vitro and in vivo

3-1 Protein Corona
The protein corona is a key factor in determining the fate of nanoparticles [12].
Previously it was found that amine modified nanoparticles bound strongly to
lipoproteins. Increased levels of lipoproteins in patients with non-ideal metabolic states,
including LDL, may alter the immune response and fate of drug carriers. Specific
binding of proteins, as opposed to nonspecific binding from plasma proteins such as
albumin, determines the circulation time and biodistribution of nanoparticles. This effect
is largely why the “stealth effect,” utilized by PEG coating, increases blood circulation
time and the mechanism behind decreased clearance and specific binding after a preincubation in albumin before injection or incubation in whole plasma. Immunoglobulin
proteins, IgG and IgM, have been shown to increase particle aggregation, which
increases clearance [56-57].
3-2 Obesity Mouse Models
Mouse Models
The mouse strains, age, diet and average weight at the time of injection are
shown on Table 3-1. I used C57BL/6J mice from Jackson Laboratory’s Diet-Induced
Obesity program (Jackson Labs; #000664) for the first three weight sets and leptindeficient mice (ob/ob) (Jackson Labs; #000632) for the obese weight set. Mice in the
lean set were fed a diet with 10% fat (Research Diets, #D12450B), whereas mice in the
other three sets were fed a diet with 60% fat (Research Diets, #D12492). Additionally
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Table 3-1. Mouse strains and injection conditions
Strain designation

Age (weeks) Diet kcal fat % Average weight (g)

C57BL/6J “Lean”

10

10

26.6

C57BL/6J “Medium” 10

60

30.7

C57BL/6J “Heavy”

16

60

38.1

Ay/J

16

60

44.2

ob/ob

12

60

55.3
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Ay/J mice were used as a model for less severe obesity compared to the ob/ob mice.
Harvested organs were imaged for individual fluorescence and used to quantify
biodistribution. Kupffer cells, macrophages from the liver, were also isolated to
determine the macrophage contribution to the high amounts of liver fluorescence.
Kupffer cells are a major factor in the liver’s immune response to foreign particles and
evading phagocytosis of these cells is a major challenge in drug delivery. Phagocytosis
is mediated by recognition of the nanoparticle surface by the Kupffer cells, which
interface with blood in the liver.
3-3 In Vitro Particle Uptake
Murine macrophages from bone marrow were used as a model for macrophage
uptake. I investigated the in vitro cell uptake using 50 nm polystyrene spheres with three
surface chemistries, pristine, carboxylate (negatively charged), and amine (positively
charged). Electron microscopy of these particles can be seen in Figure 3-1. As with the
in vivo experiments in mice, the spheres were loaded with DiR dye, a lipophilic near
infrared dye. The cells were imaged and fluoresce was measured via fluorescent
microscope and the whole cell fluorescence was quantified using ImageJ (NIH).
Fluorescence was determined by a histogram of pixel grey values from 0, black, to 255,
white, in the cell area and weighted by the multiplication of pixel count by the grey
value. A threshold value of fluorescence was determined by quantifying fluorescence of
both empty space between cells and measurements of cells without fluorescence.
Pixels of grey values below 50 (on the 0 to 255, black to white scale) were not counted
towards fluorescence via this threshold. Fluorescence in macrophages was averaged
per cell; however, due to the confluence of HepG2 cells, fluorescence was averaged
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Figure 3-1 Filomicelle and Polystyrene Structures
Filomicelles imaged on a scanning electron microscope (EM) and fluorescent
microscope loaded with DiR dye. Scale bar is 1 μm. Polystyrene particles imaged on an
electron microscope. Scale bar is 100 nm. The particle chemistries shown are pristine
polystyrene (PS), amine modified (NH3-PS) and carboxylic acid modified (COOH-PS).
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over pixel area. Amine modified spherical polystyrene nanoparticles having 50 nm
diameters (Sigma-Aldrich, #L0780-1ML) were also used. The spheres should be
removed from the circulation of mice in a matter of hours and thus the filomicelles are
more suitable for long-term biodistribution studies. My goal was to use these in vitro
experiments to elucidate the uptake of nanoparticles in varying fat environments.
3-4 Materials and Methods
Macrophage Cell Culture
To prepare latex beads, 10 μL of 1 mg/mL DiR dye (Life Technologies; #D12731)
solubilized in 20% EtOH was added to 100 μm of 50 nm amine functionalized
polystyrene spheres (Sigma Aldrich) [58]. The beads were centrifuged at 17000xg for
five minutes to remove excess dye and resuspended in PBS. Macrophages were
cultured at 37oC, 5% CO2 in media consisting of 70 % Dulbecco’s Modified Eagle
Medium, DMEM (ATCC), 10 % fetal bovine serum (FBS) and 20% LADMAC
conditioned media containing a growth factor, CGF-1. Arachidonic acid was added to
media to emulate an in vivo high fat environment at concentrations of 10mM and
100mM and incubated overnight. 100 μL of the resuspended beads were added to cell
culture and incubated for two hours. Cells were pelleted at 400xg for two minutes and
washed with PBS to remove beads that were not internalized. Cells were imaged using
an AMG EVOS fluorescent microscope and florescence per cell was quantified in
ImageJ [59]. Significance was determined using a Student's t-test. Flow cytometry was
subsequently performed on these samples using the Accuri C6 for cell counting and
fluorescence. Additional experiments were done with alternate polystyrene beads, both
pristine and functionalized with carboxylate.
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For macrophage cultures and induction of lipid droplets, oleic acid was
solubilized in bovine serum albumin (BSA) and PBS. Cultures without oleic acid were
given BSA at the same concentration that solubilized the oleic acid. The protocol for
determining cell uptake was repeated as done previously with arachidonic acid cell
cultures.
HepG2 cells were cultured in Eagle’s Minimum Essential Medium, EMEM
(ATCC), with 10% FBS and 10 mL/L of a stock Penicillin-Streptomycin solution (10,000
units penicillin and 10 mg/mL streptomycin, Sigma). HepG2 cells were incubated in
oleic acid rich media, 100 mM and 300 mM. Oleic acid concentrations of 500 mM and
greater caused a loss in cell viability. Polystyrene beads loaded with DIR dye were also
added to HepG2 cultures to determine cell uptake. Analysis in ImageJ was done by cell
area.
Mouse Tissue Harvesting and Imaging
Nanoparticles loaded with DiR dye were injected into mouse tail veins along with
controls of dye without nanocarriers and PBS. The liver, heart, lung, spleen, kidneys,
and subcutaneous WAT were harvested from mice sacrificed by cervical dislocation
under isoflurane anesthesia in accordance with the IACUC approved protocol (#22310214). Blood was collected by retro-orbital bleeding and plasma was separated through
centrifugation with a lithium heparin blood collector and plasma separator (BD
Microtainer). Fluorescence of harvested tissue was measured using an IVIS Lumina
imaging system with an ICG filter for near-IR fluorescence. Intensity of DiR dye was
quantified using Living Image software (Xenogen) and tabulated as both total organ
fluorescence and fluorescence by organ weight. Organ fluorescence was normalized by
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the data for the control PBS injection to account for background fluorescence values.
The intensity of an injection of the DiR dye without particles was also considered as a
control of injection consistency between experiments. The control mice were C57BL/6J
from the Jackson Labs diet induced obesity program. Leptin deficient ob/ob (B6.CgLepob/J) mice were used for morbidly obese mice and Ay/J (B6.Cg-Ay/J) mice were used
as a model for less extreme obesity. As suggested by the Jackson Labs diet induced
obesity program, Research Diets feed with 10% fat and 60% fat were used to induce a
range of metabolic states among the different strains. Kupffer cells from the livers were
extracted from the tissue as previously outlined by Li et al. [34]. Extracted Kupffer cells
were imaged using an AMG EVOS fluorescent microscope to determine cell
fluorescence.
3T3 Pre-adipocyte Differentiation
Fibroblasts of the 3T3 cell line were cultured on 6-well plates in growth media
consisting of DMEM (ATCC), 10% FBS (Sigma), 2mM freshly supplemented glutamine
(Sigma), 6 μg/mL biotin (Fischer Scientific) dissolved in 1M NaOH, and 10 mL/L of a
stock

Penicillin-Streptomycin

solution

(10,000

units

penicillin

and

10mg/mL

streptomycin, Sigma) for a differentiation protocol done previously by Brasaemle et al.
[60] Fibroblasts are passed before reaching confluence with a 0.25% trypsin- 0.53 mM
EDTA solution (ATCC). When differentiating, cells must reach complete confluence
before adding differentiation media. Differentiation media consists of the previously
detailed growth media, with 0.5 mM IBMX, 10 μg/ml insulin, and 10 μM dexamethasone.
Differentiated cells do not need additional fatty acid to induce the formation of lipid
droplets. Pristine 50 nm polystyrene particles loaded with DiR dye were incubated with
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differentiated adipocytes for two hours. BODIPY lipophilic dye was added to determine
co-localization of particles and lipid droplets. After incubation with dye and
nanoparticles, wells were washed with 2 mL of PBS prior to fluorescent microscopy to
remove particles not internalized or associated with the adipocytes.
3-5 Results and Discussion
Nanoparticle Biodistribution in Mice
I studied the biodistribution of nanoparticles as a function of mouse weight,
particle shape, charge and surface chemistry using ob/ob mice and diet induced
obesity. Particles used were filomicelles and polystyrene spheres (Figure 3-1). A
comparison of biodistribution as a function of weight and normalized fluorescent
intensity (Figure 3-2) shows the impact of obesity on the liver and spleen using
filomicelles as the drug carrier model. Fluorescent intensity of each organ is normalized
by the corresponding background fluorescence of organs from a PBS injection. Ay/J
mice were used as a less extreme metabolic state compared to the ob/ob mice,
however these mice still suffered from non-alcoholic fatty liver disease on a high fat diet.
While decreased liver biodistribution by weight may be a result of decreased uptake
caused by high lipid content, it is likely that the diseased livers cannot function at the
basal levels seen in healthy mice. As seen in Figure 3-2 and 3-3, the livers of a diet
induced obesity mouse show a higher uptake by mass than those with non-alcoholic
fatty liver disease considering the livers of ob/ob mice are four fold more massive.
Figure 3-3 shows that the liver uptake of nanoparticles in C57BL/6J mice on a high fat
diet is higher than both low fat diet C57BL/6J mice and high fat diet Ay/J and ob/ob
mice. The spleen does not significantly change in mass with mouse weight, and as the
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Figure 3-2 Liver and Spleen Fluorescence after Filomicelle injection
Filomicelles loaded with DiR dye were tail vein injected. Fluorescence was measured
with IVIS fluorescent imaging two days after injection and tissue harvesting. Liver (Left)
and spleen (Right). Scale bar is 1 mm.
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Figure 3-3 Liver Intensity with DiR filomicelles across mouse strains
Murine liver fluorescent intensity of DiR dye two days after injection imaged on IVIS
quantified with Living Image software. Each mouse strain represents an average of the
intensity of three mouse liver intensities relative to the background fluorescent value of
the liver of a PBS injection. Average mouse weights for each strain were: C57BL/6J low
fat, 26.6 g; C57BL/6J high fat, 38.1 g; Ay/J, 44.2 g; ob/ob, 55.3 g.
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liver and WAT increase in size the fraction of filomicelles in the spleen decreases.
Spleen uptake was reduced in C57BL/6J fed a 60% fat diet for 15 weeks, noted as
“Heavy” in our experiments, compared to lean C57BL/6J mice and ob/ob obese mice.
As the “Heavy” mice see increased liver uptake, this agrees with results in literature
where uptake to the spleen and liver are inversely proportional. These decreases
potentially represent the impact that removing drug carriers from circulation would have
on a tumor as greater potential for drug sinks exist in non-ideal metabolic states.
Organs other than the liver, spleen, and WAT show a smaller fraction of the
biodistribution and show small decreases in fluorescence as mouse size increases
(Figures 3-4, 3-5). While WAT does not increase in average intensity, indicating similar
concentrations, the increased amount of WAT linearly increases fluorescence (Figure 35). Excluding the liver, all normalized filomicelles fluorescent organ data is shown on
Figure 3-6.
The in vivo experiments in mice using filomicelles were repeated using 50 nm
spherical polystyrene particles of three surface chemistries: amine, carboxyl, pristine
polystyrene. A similar trend to filomicelle data was seen in the liver uptake (Figure 3-7)
using all three particles, particularly amine and carboxyl particles seeing decreased liver
uptake by mass. Spleen uptake did not vary significantly (Figure 3-8) as with previous
experiments. The WAT particle fraction (Figure 3-9) increases with the tissue weight
with all three particles. The normalized organ fluorescence is shown on Figure 3-10.
While organ fluorescent intensity after necropsy only shows a single time point of
particle capture, this biodistribution is useful in comparison to the fate of nanoparticles
used in cancer treatment. Both the particles removed from clearance by active sinks,
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Figure 3-4 Lung and Kidney Fluorescence
Filomicelles loaded with DiR dye were tail vein injected. Fluorescence was measured
with IVIS fluorescent imaging two days after injection. Organs shown are A, lungs and
B, kidneys. Scale bar is 1 mm.
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Figure 3-5 Heart and WAT Fluorescence
Filomicelles loaded with DiR dye were tail vein injected. Fluorescence was measured
with IVIS fluorescent imaging two days after injection. Organs shown are A, heart and
B, WAT. Scale bar is 1 mm.
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Figure 3-6 Mouse and Organ weight and fraction of fluorescent intensity
Mouse organs harvested two days after filomicelles injection, excluding liver normalized
by background fluorescence of a PBS injection. A notable difference is the
comparatively high amount of fluorescence in WAT and low intensity in the spleen of
“Heavy” mice.
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Figure 3-7 Liver intensity with NiR loaded PS spheres with modified surface
chemistry
Murine liver fluorescent intensity of DiR dye two days after 50 nm polystyrene sphere
injection taken with IVIS Lumina fluorescent imaging quantified with Living Image®
software (Xenogen). A decrease in liver uptake is seen in obese mice.
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Figure 3-8 Murine spleen fluorescent intensity taken with IVIS with polystyrene
sphere.

Spleen uptake does not vary significantly with mouse weight between comparable PS
injections.
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Figure 3-9 White adipose tissue polystyrene sphere uptake

Fluorescent intensity of white adipose tissue in lean and obese mice with multiple
polystyrene sphere chemistries. Average intensity, from particle concentration, does not
increase significantly, however the fraction of particles increases with WAT mass.

39
45

Normalized Fluorecenct Intensity

40

35

30

25

20

15

10

5

0

Lean PS

Lean PS
Amine

Lean PS
COOH

ob/ob PS

ob/ob Amine ob/ob COOH

Mouse Strain
Spleen

Lung

Heart

Kidneys

WAT

Figure 3-10 Mouse and Organ weight and fraction of fluorescent intensity
Mouse organs harvested two days after filomicelles injection, excluding liver normalized
by background fluorescence of a PBS injection. Relatively high lung fluorescence in
ob/ob mice with PS and PS-COOH injections is possibly due to particle aggregations.
Two mice died after receiving the ob/ob PS injections; as such, this data set represents
only one mouse.
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such as the liver and spleen, and those that are passive such as white adipose tissue,
limit the available drug for treatment of the intended target and increase the necessary
effective dose. Mice with fur, particularly the black fur of C57BL/6J and ob/ob mice
make it difficult to measure organ fluorescence in vivo using IVIS fluorescent imaging.
For future experiments, nude or shaved mice could be used to image living mice with
near infrared dye at multiple time points in vivo. This would allow for the IVIS to detect
fluorescence in the live mice to get real time biodistribution changes. Blood collection
and a Western blot with PEG as the epitope tag to determine circulating PEG levels
could also be used to measure freely circulating drug carriers over time.
Nanoparticle Uptake in vitro
I studied the cellular uptake of nanoparticles in varying levels of arachidonic acid and
oleic acid, which simulate a cell environment caused by a diet high in fat [47].
Arachidonic acid was initially chosen for the enhanced ability to induce lipid droplets in
macrophages. However, while present in physiological settings, arachidonic acid, a 21:4
fatty acid, would not be a primary component of lipid droplets in vivo. Arachidonic acid
may also act as a signaling molecule and change the activity of the macrophages;
however, this does not appear to be the case as results using oleic acid and arachidonic
acid showed similar trends [61-62]. The shorter chain, less saturated fatty acids, oleic
acid and palmitic acid, 18:1 and 16:0 fatty acids respectively, are primary components
of the high fat diet fed to my mice in obesity studies. I repeated these studies with oleic
acid induced lipid droplets to reproduce the results in a more representative
physiological setting. The formation of lipid droplets was induced using both oleic and
arachidonic acid (Figure 3-11) in macrophages and HepG2 cells. For both positively
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Figure 3-11 Lipid Droplets in Murine Macrophages

Lipid Droplets formed in 10 μM arachadonic acid stained with BODIPY (green). Scale
bar 10 μm
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charged amine coated polystyrene beads and pristine polystyrene beads, I saw an
increase in uptake (p < 0.05) in macrophages with high amounts of both oleic and
arachidonic acid compared to no additional fat. (Figure 3-12) Both arachidonic acid and
oleic acid were able to produce a comparative increase in size and number of lipid
droplets with increased fatty acid in media. The increase in lipid droplet formation can
be seen in Figure 3-13 where lipids are stained with BODIPY. Increasing fatty acid
content typically increases both the size and quantity of lipid droplets in these
macrophage experiments. The DiR dye loaded into nanoparticles does not exclusively
localize to lipid droplets in macrophages despite the relationship between fatty acid
concentration and internalization although there may be some association between the
particles and the lipid droplet surface.
Carboxylate modified polystyrene beads did not show any significant trend based
on fatty acid concentration. These experiments produced a comparatively lower amount
of particle uptake compared to the pristine and amine functionalized beads. While most
cells showed little uptake, some regions of cells showed extremely high points of
fluorescence, which led to high standard deviation and little statistical significance
between oleic acid concentrations. As seen in Figures 3-14 and 3-15 the uptake of
particles was minimal with carboxylate beads and did not vary with increased oleic acid
as in pristine polystyrene beads. These results agree with previous immune studies,
which found that nanoparticles with negative charge at physiological pH—specifically
surfaces modified with carboxyl functional groups—have reduced cell uptake and
immune detection. However size is often a stronger predictor of cell uptake than charge
[18]. The carboxylate nanoparticles had a tendency to form large aggregates especially
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Figure 3-12 Average fluorescence per macrophage in elevated oleic acid oleic
acid
Cells were incubated with 50 nm Amine modified polystyrene beads loaded with DiR
near infrared dye. Cells were imaged on a fluorescent microscope and fluorescence
was quantified using ImageJ. Representing the Student’s t-test, “ * ”shows p < 0.05
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Figure 3-13 Lipid droplet formation in macrophages in oleic acid rich media
Lipid droplets are stained with BODIPY dye. Scale bar is 10 μm.
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Figure 3-14 Nanoparticle uptake in macrophages incubated in increasing fatty
acid
50 nm Polystyrene spheres and filomicelles incubated in macrophage culture for 2
hours. Results were similar in oleic and arachidonic acid; in this figure, pristine
polystyrene spheres and filomicelles were incubated in oleic acid and amine spheres
were incubated in arachidonic acid. DiR dye loaded into nanoparticles is shown in red.
Scale bar is 10 μm.
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Figure 3-15 Carboxylated polystyrene bead uptake in murine macrophages.

50 nm Carboxylated polystyrene spheres incubated in macrophage culture for 2 hours.
DiR dye loaded into nanoparticles is shown in white. Scale bar 10 μm.
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in the presence of proteins and, while the beads were sonicated and centrifuged to
remove large aggregates, it is possible the nanoparticles formed these complexes in the
protein rich cell media. These carboxyl functionalized particles saw uptake in vivo, with
similar localization in the spleen and liver as other nanoparticles, including isolated
Kupffer cells. The fluorescent DiR dye does not fluoresce significantly outside of the
nanoparticles. To show the measured macrophage fluorescence was due nanoparticle
uptake and not due to the DiR dye alone, the dye was added to macrophages without
particles. As seen in Figure 3-16, the macrophages with dye alone did not show
significant fluorescence compared to the nanoparticle incubations.
HepG2 cells required higher concentrations of oleic acid for significant changes
in nanoparticle uptake. My experiments found a drop in cell viability at concentrations of
500 μM and higher. Similar to the macrophages, higher levels of lipid droplets resulted
in a higher cell uptake with polystyrene beads (Figure 3-17) resulting in a significant
difference in fluorescence (p < 0.01). To ensure measured fluorescence was a result of
particle internalization, cells were washed with PBS, before imaging. The HepG2
experiments showed similar trends with fatty acid concentration compared to those with
macrophages.
To explore extreme cases of metabolic states, adipocytes were differentiated
from 3T3 fibroblasts. As with adipocytes in the body, these cells produce large lipid
droplets without additional fatty acid in media. As done with macrophages and HepG2
cells, polystyrene beads loaded with DiR dye were incubated for two hours. To
determine co-localization of nanoparticles with lipid droplets, the lipid marker BODIPY
493/503 was also added. While the polystyrene particles do not appear to be
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Figure 3-16 Murine Macrophages with DiR dye without nanoparticles
Macrophages incubated in with and without oleic acid with DIR dye added as done with
nanoparticles. DiR dye does not show significant fluorescence without nanoparticles.
While

some

cells

showed

some

fluorescence,

concentrations was not significant. Scale bar is 10 μm.

the

difference

between
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Figure 3-17 HepG2 Polystyrene Particle uptake in Oleic Acid
HepG2 hepatocytes were incubated in oleic acid rich media overnight. Polystyrene
beads were then incubated for 2 hours. Following a wash with PBS, cells were
visualized on a fluorescent microscope. Due to the confluence of the HepG2 cells,
fluorescence was quantified per cell area rather than per cell. Student’s t-test p< 0.01
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internalized by lipid droplets in adipocytes, the overlay of DiR and BODIPY 493/503 dye
at the periphery of lipid droplets, seen as a red circle around the green lipid droplets
(Figure 3-18), shows an association between the particles and the surface of the lipid
droplets. The surface association of the nanoparticles may suggest they are trafficked to
the surface of the lipid droplets. This transport may contribute to the increase in particle
internalization in high fatty acid concentrations seen in these experiments.
Previous experiments by Lundqvist et al. showed that lipoproteins bind to a
variety of nanoparticle surface chemistries in both a charge and size dependent
manner, with 50 nm amine modified beads showing affinity to the most lipoproteins [58,
63]. These lipoprotein levels are increased in obese mice, which may have an effect on
particle fate. My results in ob/ob and diet induced obesity mice showed the impact of
body composition as related to biodistribution. These results go beyond simple
increased ratio of fat tissue of whole mouse mass that would be expected from a simple
mass balance leaving less drug available to targets.
Larger livers in ob/ob mice do not result in a proportional increase in
nanoparticles. Non-alcoholic fatty liver disease interferes with hepatocellular clearance,
negatively affecting the activation and signaling of Kupffer cells [36]. Fluorescent
Kupffer cells isolated from the livers of C57BL/6J mice after carboxylated polystyrene
bead injection is shown in Figure 3-20. More data is needed to quantify the difference
between Kupffer cell uptake as a result of nanoparticle injections. Comparisons from
experiments previous to this macrophage isolation showed the average fluorescence
per cell area in the in vitro experiments is typically ten-fold higher in the cultured
macrophages than that of HepG2 cells. As the macrophages appear to internalize a
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Figure 3-18 Merged Fluorescent microscopy of polystyrene particles and lipid
droplets in Murine Adipocytes
Differentiated Adipocytes from the 3T3 cell line were incubated with 50 nm polystyrene
spheres loaded with DiR dye, shown in red, for two hours. Lipid droplets stained with
BODIPY, shown in green. Scale bar is 10 μm.
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Figure 3-19 Isolated Kupffer cells after carboxylate polystyrene injection in
C57BL/6J mice

Fluorescent microscopy of Kupffer cells extracted from the combined livers of three
C57BL/6J mice on a low fat diet, two days after COOH modified polystyrene bead
injection, loaded with DiR dye.

53
greater number of particles, this agrees with the idea that a disruption in Kupffer cell
activity is a large contributing factor in the lower than expected liver uptake in ob/ob and
Ay/J mice with fatty liver disease.
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Chapter 4: Conclusions and Future Work

4-1 Conclusion
I have shown that obesity affects the biodistribution of model nanoparticles in
mice. I used three mouse models of obesity: diet induced, Ay/J, and ob/ob. The
localization of nanoparticles to the liver increases in diet induced obese mouse models.
However, this trend does not continue in advanced cases of obesity where animals
have developed NAFLD. I confirmed these finding in vitro using cultured macrophages,
hepatocytes, and adipocytes. Oleic acid and arachidonic acid were used in vitro to
emulate a diet high in fat, which influenced particle uptake. Macrophages and
hepatocytes showed a significant increase in particle uptake with increased fatty acid
media with both pristine polystyrene beads and amine modified beads in vitro. The
results of nanoparticle injections in diet induced obesity mice with healthy livers
compared to Ay/J and ob/ob with NAFLD show that this effect may only be present in
normally functioning livers.
Due to the role of Kupffer cells in the signaling of non-alcoholic fatty liver disease,
the change in liver uptake in ob/ob and Ay/J mice is not surprising. Kupffer cells act as
one of the primary factors of particle clearance in the liver. A disruption in Kupffer cell
function would result in diminished liver function. Preliminary isolations of Kupffer cells
from mice showed it may be possible to compare the fluorescence of these isolated
macrophages between mouse models and different nanoparticle injections. Exploring
the changes in the body in non-ideal metabolic states is vital in understanding drug
efficacy and fate.

55
4-2 Future Work
Future work should expand on the interaction of nanoparticles with the immune
system in obese mouse models and explore the signaling and response to
nanoparticles in high fat environments and in models for related diseases such as
diabetes. Obese mouse models and protein interactions with nanotechnologies should
be considered in all future drug development to ensure the highest chance of
effectiveness at the clinical level. Design considerations such as surface chemistry and
charge are already considered to minimize undesirable side effects and immune
response. These parameters should also be tuned to minimize obesity related pitfalls of
drug delivery, specifically minimizing the specific binding affinity of lipoproteins. To
design successful drugs, the development must consider the constraints that will affect
the real world treatment efficacy already seen by dosing complications in obese
patients.
Research has been done where nanoparticles have been pre-incubated in whole
or fractions of blood plasma before either determining particle clearance in vivo or
particle internalization in vitro. Using both specific and non-specific protein-nanoparticle
interactions, it could be determined which plasma proteins that increase with non-ideal
metabolic states such as lipoproteins, can specifically accelerate or prolong blood
clearance and alter the biodistribution. Preincubation of nanoparticles with HDL and
LDL cholesterol and their protein components could be studied with macrophage
particle internalization in media increasing amounts of fatty acids. Additionally these
particle uptake studies should be done with in vitro cancer models in the presence of
increasing fatty acid concentrations.
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The in vitro experiments in macrophages and hepatocytes were done after an
overnight incubation in fatty acid. At this point most free fatty acid has been
incorporated into lipid droplets. It’s possible the transport of drug carriers into cells could
be affected in areas were excess fatty acid is present, which may be relevant as obesity
progresses in the body. Nanoparticle internalization may be increased as fatty acid is
incorporated into lipid droplets. The potential surface association with nanoparticles and
lipid droplets could be explored through an isolation of lipid droplets. Lipid droplets can
be isolated from lysed cells through ultracentrifugation and the associated nanoparticles
could be quantified outside the cell. Although DiR dye without nanoparticles did not
produce significant fluorescence in macrophages and hepatocytes, the trafficking of
particles could be decoupled from dye by using drug carrier with bound fluorophore
rather than hydrophobic association. Dye may diffuse out of the polystyrene spheres
and associate with the surface of lipid droplets rather than the nanoparticles.
As the future direction of drug delivery involves actively targeted treatment,
examining how the changes in a non-ideal metabolic state change targeting affinity and
particle internalization should be the focus of additional research. Many functionalized
nanoparticles employ targeting strategies that improve internalization, especially in drug
resistant cancers. Since I have found internalization to be affected by fatty acid
concentration, these targeting moieties could experience altered macrophage particle
uptake in the presence of fatty acid. For the ultimate goal of improved drug efficacy and
targeting, these internalization experiments can also be done in vitro with various
cancer models such as those of B-cell lymphocytes.
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Figure A-1 Murine plasma depletion gradient
Example protein gel depicting the supernatants and pellet of protein-nanoparticle
incubations. Lanes eight through ten are plasma without nanoparticles.
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Figure A-2 Fluorescent Intensity per organ across mouse strains and diets
Total fluorescent intensity, measured as photon flux, was taking using IVIS fluorescence
imaging. Data was normalized by the PBS control injection in each group, representing
changes in background fluorescence. OB3 represents the PEG-PBD filomicelles.
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Figure A-3 Comparison of washed and unwashed HepG2 Fluorescence

Comparison of HepG2 fluorescence before and after a wash with PBS. Washing with
PBS removes loosely associated and free particles while leaving adherent HepG2 cells
and particles that are surface associated and phagocytosed.
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Figure A-4 Filomicelle and PBS control injection histology of liver and kidneys

Histology comparing filomicelle injections to PBS control. The filomicelles did not show
significant changes from control injections.
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Figure A-5 LADMAC cell culture

LADMAC Bone marrow cells used to produce CSF-1 rich media, a colony stimulating
factor used in the proliferation of macrophages.
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Figure A-6 HepG2 Lipid Droplets
HepG2 culture with lipids marked with green fluorophore.
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